Medical/Pharmaceuticals
MEDICAL IP Received US FDA 510(k) Clearance for DeepCatch, AI Software for Whole-Body Composition CT Quantification
* The world's first FDA cleared solution that automatically analyzes bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system in whole-body CT * Validation using multi-site and multi-racial CT data in the US… "We will create a new global standard for body com...
2023-06-26 19:00
3207
United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI
With uMI Panorama™, United Imaging Continues to Push the Envelope on Whole-Body System Performance HOUSTON, June 25, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and a Leadership Circle sponsor at this year's SNMMI, is ...
2023-06-26 00:00
3384
SK pharmteco doubles viral vector production capacity in Europe
* Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing footprint to10,000m2, one of the largest inEurope * Operation of the second facility to kick sta...
2023-06-23 07:30
3250
Bergen Conference Marks 150 Years Since Discovery of the Leprosy Bacillus
TOKYO, June 22, 2023 /PRNewswire/ -- A two-day conference commemorating the discovery of the bacillus that causes leprosy 150 years ago took place in Bergen, Norway, on June 21-22, 2023. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative and the University of Bergen, the conference i...
2023-06-22 22:00
2993
I-Mab Announces the Appointment of Raj Kannan as CEO
GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan...
2023-06-22 20:00
3313
PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DS...
2023-06-22 19:00
3118
Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry
TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...
2023-06-22 13:00
2682
BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease
WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controll...
2023-06-22 08:02
2954
Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology
SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner
2023-06-21 23:07
3567
Mediso receives FDA approval for InterView™ nuclear medicine image processing software
BUDAPEST, Hungary, June 21, 2023 /PRNewswire/ -- Mediso
2023-06-21 16:00
2786
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered inTokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of...
2023-06-21 09:00
3635
Growing Awareness of Brain Health for Senior Dogs as Cascade Animal Sciences Launches "Neuro-Pro"
ATLANTA, June 20, 2023 /PRNewswire/ -- Cascade Animal Sciences, an animal health start-up based inthe United States and Australia, is proud to announce the launch of its first dietary supplement product "Neuro-Pro". Neuro-Pro is designed for middle-to-senior-aged dogs and dogs that require neuro...
2023-06-20 22:17
3158
Clarity commences COMBAT theranostic prostate cancer trial in the US
SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its64C...
2023-06-20 21:03
2893
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 ...
2023-06-20 21:00
2572
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...
2023-06-20 18:30
6031
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...
2023-06-20 08:01
2001
Bergen Prepares to Host International Conference on Hansen's Disease Marking 150 Years Since the Discovery of the Leprosy Bacillus
TOKYO, June 19, 2023 /PRNewswire/ -- The Sasakawa Leprosy (Hansen's Disease) Initiative and theUniversity of Bergen are organizing a two-day conference in Bergen, Norway, on June 21-22, 2023, to commemorate the 150th anniversary of the discovery ofM. leprae, the causative agent of leprosy, in 187...
2023-06-19 19:00
2376
The Summit Forum on the Application and Construction of AGP in China Takes Place in Shenzhen
SHENZHEN, China, June 19, 2023 /PRNewswire/ -- On June 9, the Summit Forum on the Application and Construction of AGP inChina, led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and Digital Therapeutics R&D Center (hereafter referred to as the "R&D Center")...
2023-06-19 16:00
3051
MoyoAssist® Extra-VAD, a Promising Solution for Short-to-Medium-Term Ventricular Assist for China NMPA trial, Showcased at 4th Academic Annual Conference of CSBE
SUZHOU, China, June. 16, 2023 /PRNewswire/ -- The 4th Academic Annual Conference held by the Mechanical Circulatory Support (MCS) Branch of the Chinese Society of Biomedical Engineering (CSBE), one of the biggest academic gatherings that celebrate the latest accomplishments in technological inn...
2023-06-17 07:04
4548
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer
NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other m...
2023-06-16 22:01
3127
Week's Top Stories
Most Reposted
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 268 media titles]
2026-10-01 10:00
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 261 media titles]
2026-10-02 16:27
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23617
